Sentinel node detection in pre-operative axillary staging

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue SUPPL. 1, 2004, Pages

  Trifirò, Giuseppe ^a   Viale, Giuseppe ^a   Gentilini, Oreste ^a   Lavinia Travaini, Laura ^a   Paganelli, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer; Lymphoscintigraphy; Radiocolloid; Sentinel lymph node; Sentinel lymph node biopsy

Indexed keywords

ANTIMONY TECHNETIUM SULFIDE TC 99M; CYTOKERATIN ANTIBODY; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MNF 116; NANOCOLL TC 99M; PEROXIDASE; POLYMER; TECHNETIUM 99M; TECHNETIUM SULFUR COLLOID TC 99M; TRACER; UNCLASSIFIED DRUG;

AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST CANCER; BREAST DUCT; BREAST DUCTAL CARCIOMA IN SITU; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC ACCURACY; FEMALE; FROZEN SECTION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LOCAL ANESTHESIA; LYMPH NODE DISSECTION; LYMPHOSCINTIGRAPHY; METASTASIS; MINIMALLY INVASIVE SURGERY; MORBIDITY; PARTICLE SIZE; PREGNANCY; PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY;

EID: 3042679796     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1526-9     Document Type: Review

References (95)

1. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-399.
2. Giuliano AE, Jones RC, Brennan M, Statman RR. Sentinel lymphadenectomy and breast cancer. J Clin Oncol 1997; 15: 2345-2350.
3. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 22:567-575.
4. Veronesi U, Luini A, Galimberti V, Marchini S, Sacchini V, Rilke F. Extent of axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol 1990; 16:127-133.
5. Zurrida S, Morabito A, Galimberti V, et al. Importance of the level of axillary involvement in relation to traditional variables in the prognosis of breast cancer. Int J Oncol 1999; 15:475-480.
6. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid AD in breast cancer with clinically negative lymph-nodes. Lancet 1997; 349:1864-1867.
7. Paganelli G, De Cicco C, Cremonesi M, et al. Optimized sentinel node scintigraphy in breast cancer. Q J Nucl Med 1998; 42:49-53.
8. De Cicco C, Cremonesi M, Luini A, Bartolomei M, Grana C, Prisco G, Galimberti V, Calza P, Viale G, Veronesi U, Paganelli G. Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. J Nucl Med 1998; 39:2080-2084.
9. Hill AD, Tran KN, Yeung H, Yeh SD, Borgen PI, Cody HS 3rd. Sentinel lymph node biopsy in breast cancer: unfiltered radioisotope is superior to filtered. J Am Coll Surg 1999; 188:377-381.
10. Cody HS 3rd, Borgen PI. State-of-the-art approaches to sentinel node biopsy for breast cancer: study design, patient selection, technique, and quality control at Memorial Sloan-Kettering Cancer Center. Surg Oncol 1999; 8:85-91.
11. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma-probe. Surg Oncol 1993; 2:335-340.
12. Wilhelm AJ, Mijnhout GS, Franssen EJF. Radiopharmaceuticals in sentinel lymph-node detection-an overview. Eur J Nucl Med 1999; 26 (Suppl):S36-S42.
13. Mariani G, Moresco L, Viale G, Villa G, Bagnasco M, Canavese G, Buscombe J, Strauss HW, Paganelli G. Radioguided sentinel lymph node biopsy in breast cancer surgery. J Nucl Med 2001; 42:1198-1215.
14. Tanis PJ, Valdes Olmos RA, Muller SH, Nieweg OE. Lymphatic mapping in patients with breast carcinoma: reproducibility and lymphoscintigraphic results. Radiology 2003; 228:313-315.
15. Roumen RM, Geuskens LM, Valkenburg JG. In search of the true sentinel node by different injection techniques in breast cancer patients. Eur J Surg Oncol 1999; 25:347-351.
16. Klimberg VS, Rubio IT, Henry R, Cowan C, Colvert M, Korourian S. Subareolar versus peritumoural injection for location of the sentinel lymph node. Ann Surg 1999; 229:860-864.
17. Spratt JS, Schieber W, Dillard B. Anatomy and surgical technique of groin dissection. St. Louis: CV Mosby, 1965.
18. Alazraki NP, Styblo T, Grant SF, Cohen C, Larsen T, Aarsvold JN. Sentinel node staging of early breast cancer using lymphoscintigraphy and the intraoperative gamma-detecting probe. Semin Nucl Med 2000; 30:56-64.
19. Paganelli G, Galimberti V, Trifirò G, Travaini L, De Cicco C, Mazzarol G, Intra M, Rocca P, Prisco G, Veronesi U. Internal mammary node lymphoscintigraphy and biopsy in breast cancer. Q J Nucl Med 2002; 46:138-144.
20. De Cicco C, Baio SM, Veronesi P, Trifirò G, Ciprian A, Prisco G, Vento A, Rososchansky J, Viale G, Paganelli G. Sentinel node biopsy in male breast cancer. Nucl Med Commun 2004:in press.
21. Luini A, Gatti G, Frasson A, et al. Sentinel lymph node biopsy performed with local anesthesia in patients with early-stage breast carcinoma. Arch Surg 2002; 137:1157-1160.
22. Borgstein PJ, Pijpers R, Comans EF, et al. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998; 186:275-283.
23. Borgstein PJ, Meijr S, Pijpers R. Intradermal blue dye to identify sentinel lymph node in breast cancer. Lancet 1997; 349:1668-1669.
24. Borgstein PJ, Meijer S, Pijpers RJ, van Diest PJ. Functional lymphatic anatomy in breast cancer: echoes from the past and the periareolar blue method. Ann Surg 2000; 232:81-89.
25. Roumen RM, Geuskens LM, Valkenburg JG. In search of the true sentinel node by different injection techniques in breast cancer patients. Eur J Surg Oncol 1999; 25:347-351.
26. Borgstein P, Meijier S. Historical perspective of lymphatic tumour spread and the emergence of the sentinel node concept. Eur J Surg Oncol 1998; 24:85-89.
27. Keshtgar MRS, Ell PJ. Sentinel lymph node detection and imaging. Eur J Nucl Med 1999; 26:57-67.
28. Morton DL, Chan AD. The concept of sentinel node localization: how it started. Semin Nucl Med 2000; 30:4-10.
29. Handley RS, Trackray AC. Invasion of internal mammary lymph nodes in carcinoma of the breast. Br Med J 1954; 1:61-63.
30. Noguchi M, Tsugawa K, Miwa K. Internal mammary chain sentinel lymph node identification in breast cancer patient. J Surg Oncol 2000; 73:75-80.
31. Cox CE, Bass SS, Reintgen DS. Techniques for lymphatic mapping in breast carcinoma. Surg Oncol Clin North Am 1999; 8:447-468.
32. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349:546-553.
33. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220:391-401.
34. Krag DN, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer - a multicenter validation study. N Engl J Med 1998; 339:941-946.
35. Wilke LG, Giuliano AE. Sentinel lymph node biopsy in patients with early-stage breast cancer: status of the National Clinical Trials. Surg Clin North Am 2003; 83:901-910.
36. Ross MI. Sentinel lymph node dissection in early-stage breast cancer: ongoing prospective randomized trials in the USA. Ann Surg Oncol 2001; 8:778-818.
37. Krag DN, Julian T. Expert perspectives: update on NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection for clinically node-negative breast cancer. Breast Dis Year Book Q 2002; 13:113-114.
38. Grube BJ, Giuliano AE. Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ASOCOG Z0011 trial. Semin Surg Oncol 2001; 20:230-237.
39. Breast Study announcements. Durham, N.C.: American College of Surgeons Oncology Group, 2003. (Accessed July 18, 2003 at www.asocog.org/studies/ organ_site/breast/.)
40. Hurkmans CW, Borger JH, Rutgers EJ, et al. Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023. Radiother Oncol 2003; 68:233-240.
41. Clarke D, Khonji NI, Mansel ER. Sentinel node biopsy in breats cancer: ALMANAC trial. World J Surg 2001; 25:819-822.
42. Schwartz GF, Giuliano AE, Veronesi U. Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 2002; May 15; 94:2542-2551.
43. Bedrosian I, Reynolds C, Mick R, et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 2000; 88:2540-2545.
44. Cohen LF, Breslin TM, Kuerer HM, Ross MI, Hunt KK, Sahin AA. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol 2000; 24:1266-1272.
45. Nason KS, Anderson BO, Byrd DR, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000; 89:2187-2194.
46. Brady EW. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Breast J 2002; 8:97-100.
47. Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000; 18:3480-3486.
48. Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002; 9:235-242.
49. Mamounas EP. Sentinel lymph node biopsy after neoadjuvant systemic therapy [review]. Surg Clin North Am 2003; 83:931-942.
50. Schwartz GF, Meltzer AJ. Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast. Breast J 2003; 9:374-379.
51. Sabel MS, Schott AF, Kleer CG, et al. Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg 2003; 186: 102-105.
52. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-2493.
53. Andea AA, Wallis T, Newman LA, Bouwman D, Dey J, Visscher D. Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma. Cancer 2002; 94:1383-1390.
54. Anderson BO. Sentinel lymphadenectomy in breast cancer: an update on the NCCN Clinical Practice Guidelines. J Natl Copr Cancer Network 2003; 1:S64-S70.
55. Reintgen D, Giuliano R, Cox G. Lymphatic mapping and sentinel lymph node biopsy for breast cancer. Cancer J 2002; 8:S15-S21.
56. Ozmen V, Muslumanoglu M, Cabioglu N, et al. Increased false negative rates in sentinel lymph node biopsies in patients with multifocal breast cancer. Breast Cancer Res Treat 2002; 76:237-244.
57. Grant RN, Tabah EJ, Adair FE. The surgical significance of the subareolar plexus in cancer of the breast. Surgery 1959; 33:71-78.
58. Schrenk P, Wayand W. Sentinel-node biopsy in axillary lymph-node staging for patients with multicentric breast cancer. Lancet 2001; 357:122.
59. Kim HJ, Heerdt AS, Cody HS III, Van Zee KJ. Sentinel node drainage in multicentric breast cancers. Breast J 2002; 8:356-361.
60. Tousimis E, Van Zee KJ, Fey JV, et al. The accuracy of sentinel lymph node biopsy in multicentric and multifocal invasive breast cancers. J Am Coll Surg 2003; 197:529-535.
61. Kumar R, Jana S, Heiba SI, et al. Retrospective analysis of sentinel node localization in multifocal, multicentric, palpable, or nonpalpable breast cancer. J Nucl Med 2003; 44:7-10.
62. McMaster KM, Giuliano AE, Ross MI, et al. Sentinel-lymphnode biopsy for breast cancer-not yet the standard of care. N Engl J Med 1998; 339:990-995.
63. Ollila DW, Giuliano AE. Intraoperative lymphatic mapping and sentinel lymphadenectomy using isosulfan blue dye. Breast Dis 1998; 8:297-300.
64. Wong SL, Edwards MJ, Chao C, et al. The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy. Ann Surg Oncol 2002; 9:272-277.
65. Miner TJ, Shriver CD, Jaques DP, Maniscalco-Theberge ME, Krag DN. Sentinel lymph node biopsy for breast cancer: the role of previous biopsy on patients eligibility. Am Surg 1999; 65:493-499.
66. Schnitt SJ, Silen W, Sadowsky NL, et al. Ductal carcinoma in situ. N Engl J Med 1988; 318:898-902.
67. Pendas S, Dauway E, Giuliano R, Ku NN, Cow CE. Sentinel node biopsy in DCIS patients. Ann Surg Oncol 2000; 7:15-20.
68. Klauber-DeMore N, Tan LK, Liberman L, et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2000; 7:636-642.
69. Cox CE, Nguyen K, Gray RJ, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am J Surg 2001; 67:513-519.
70. Intra M, Veronesi P, Mazzarol G, et al. Axillary sentinel lymph node biopsy in pafients with pure ductal carcinoma in situ of the breast. Arch Surg 2003; 138:309-313.
71. Carter BA, Jensesn RA, Simpson JF, Page DL. Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Pathol 2000; 113:259-265.
72. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics 2000. CA Cancer J Nlin 2000; 50:7-33.
73. Salvadori B, Saccozzi R, Manzari A, Andreola S, Conti RA, Cusumano F, Grassi M. Prognosis in breast cancer in males: an analysis of 170 cases. Eur J Cancer 1994; 7:930-935.
74. Maijer-van Gelder ME, Look MP, Bolt-de Vries J, Peters HA, Kijn JGM, Foekens JA. Clinical relevance of biologic factors in male breast cancer. Breast Cancer Res Treat 2001; 68: 249-260.
75. Rush Port E, Fey JV, Cody HS, Borgen PI. Sentinel lymph node biopsy in patients with male breast cancer. Cancer 2001; 91:319-323.
76. Gennari R, Renne G, Travaini L, Bassi F, Zurrida S. Sentinel node biopsy in male breast cancer: future standard treatment? Eur J Surg 2001; 167:461-462.
77. Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg 2003; 138:91-99.
78. Nicklas A, Baker M. Imaging strategies in pregnant cancer patients. Semin Oncol 2000; 27:623-632.
79. Morita ET, Chang J, Leong SP. Principles and controversies in lymphoscintigraphy with emphasis on breast cancer. Surg Clin North Am 2000; 80:1721-1739.
80. Fenaroli P, Tondini C, Motta T, Virotta G, Personenin A. Axillary sentinel node biopsy under local anesthesia in early breast cancer. Ann Oncol 2000; 11:1617-1618.
81. Viale G, Bosari S, Mazzarol G, Galimberti V, Luini A, Veronesi P, Paganelli G, Bedoni M, Orvieto E. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer 1999; 85:2433-2438.
82. Chilosi M, Lestani M, Pedron S, Montagna L, Benedetti A, Pizzolo G, Menestrina F. A rapid immunostaining method for frozen sections. Biotech Histochem 1994; 69:235-239.
83. Hermanek P, Hutter RVP, Sobin LH, Wittekind C. International Union Against Cancer. Classification of isolated tumour cells and micrometastasis. Cancer 1999; 86:2668-2673.
84. International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancer. Lancet 1990; 335:1565-1568.
85. Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node micrometastases from breast carcinoma. Reviewing the dilemma. Cancer 1997; 80:1188-1197.
86. Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Gusterson B, Neville AM. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. Lancet 1999; 354:896-900.
87. Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999; 229:536-541.
88. Reynolds C, Mick R, Donohue JH, Grant CS, Farley DR, Callans LS, Orel SG, Keeney GL, Lawton TJ, Czemiecki BJ. Sentinel lymph node biopsy with metastasis: can AD be avoided in some patients with breast cancer? J Clin Oncol 1999; 17:1720-1726.
89. Viale G, Maiorano E, Mazzarol G, Zurrida S, Galimberti V, Luini A, Renne G, Pruneri G, Maisonneuve P, Veronesi U. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 2001; 92:1378-1384.
90. Turner RR, Chu KU, Qi K, Botnick LE, Hansen NM, Glass EC, Giuliano AE. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 2000; 89:574-581.
91. Masuda N, Tamaki Y, Sakita I, Ooka M, Ohnishi T, Kadota M, Aritake N, Okubo K, Monden M. Clinical significance of micrometastases in axillary lymph nodes assessed by reverse transcription-polymerase chain reaction in breast cancer patients. Clin Cancer Res 2000; 6:4176-4185.
92. Bostick PJ, Chatteriee S, Chi DD, Huynh KT, Giuliano AE, Cote R, Hoon DS. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 1998; 16:2632-2640.
93. Bostick PJ, Huynh KT, Sarantou T, Turner RR, Qi K, Giuliano AE, Hoon DS. Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple-marker RT-PCR. Int J Cancer 1998; 79:645-651.
94. Kataoka A, Mori M, Sadanaga N, Ueo H, Tsuji K, Ray Y, Barnard GF, Sugimachi K. RT-PCR detection of breast cancer cells in sentinel lymph nodes. Int J Oncol 2000; 16:1147-1152.
95. Manzotti M, Dell'Orto P, Maisonneuve P, Zurrida S, Mazzarol G, Viale G. Reverse transcription-polymerase chain reaction assay for multiple mRNA markers in the detection of breast cancer metastases in sentinel lymph nodes. Int J Cancer 2001; 95:307-312.